PURPOSE: Proteomics technologies are well suited for harnessing the immune response to tumor antigens for diagnostic applications as in the case of breast cancer. We previously reported a substantial impact of hormone therapy (HT) on the proteome. Here, we investigated the effect of HT on the immune response toward breast tumor antigens. EXPERIMENTAL DESIGN: Plasmas collected 0-10 months prior to diagnosis of ER+ breast cancer from 190 postmenopausal women and 190 controls that participated in the Women's Health Initiative Observational Study were analyzed for the effect of HT on IgG reactivity against arrayed proteins from MCF-7 or SKBR3 breast cancer cell line lysates following extensive fractionation. RESULTS: HT user cases exhibited significantly reduced autoantibody reactivity against arrayed proteins compared to cases who were Not Current users. An associated reduced level of IL-6 and other immune-related cytokines was observed among HT users relative to nonusers. CONCLUSION AND CLINICAL RELEVANCE: Our findings suggest occurrence of a global altered immune response to breast cancer-derived proteins associated with HT. Thus a full understanding of factors that modulate the immune response is necessary to translate autoantibody panels into clinical applications.
PURPOSE: Proteomics technologies are well suited for harnessing the immune response to tumor antigens for diagnostic applications as in the case of breast cancer. We previously reported a substantial impact of hormone therapy (HT) on the proteome. Here, we investigated the effect of HT on the immune response toward breast tumor antigens. EXPERIMENTAL DESIGN: Plasmas collected 0-10 months prior to diagnosis of ER+ breast cancer from 190 postmenopausal women and 190 controls that participated in the Women's Health Initiative Observational Study were analyzed for the effect of HT on IgG reactivity against arrayed proteins from MCF-7 or SKBR3breast cancer cell line lysates following extensive fractionation. RESULTS: HT user cases exhibited significantly reduced autoantibody reactivity against arrayed proteins compared to cases who were Not Current users. An associated reduced level of IL-6 and other immune-related cytokines was observed among HT users relative to nonusers. CONCLUSION AND CLINICAL RELEVANCE: Our findings suggest occurrence of a global altered immune response to breast cancer-derived proteins associated with HT. Thus a full understanding of factors that modulate the immune response is necessary to translate autoantibody panels into clinical applications.
Authors: Marcia L Stefanick; Garnet L Anderson; Karen L Margolis; Susan L Hendrix; Rebecca J Rodabough; Electra D Paskett; Dorothy S Lane; F Allan Hubbell; Annlouise R Assaf; Gloria E Sarto; Robert S Schenken; Shagufta Yasmeen; Lawrence Lessin; Rowan T Chlebowski Journal: JAMA Date: 2006-04-12 Impact factor: 56.272
Authors: Per Hall; Alexander Ploner; Judith Bjöhle; Fei Huang; Chin-Yo Lin; Edison T Liu; Lance D Miller; Hans Nordgren; Yudi Pawitan; Peter Shaw; Lambert Skoog; Johanna Smeds; Sara Wedrén; John Ohd; Jonas Bergh Journal: BMC Med Date: 2006-06-30 Impact factor: 8.775
Authors: Charles Kooperberg; Mary Cushman; Judith Hsia; Jennifer G Robinson; Aaron K Aragaki; John K Lynch; Alison E Baird; Karen C Johnson; Lewis H Kuller; Shirley A A Beresford; Beatriz Rodriguez Journal: PLoS Clin Trials Date: 2007-06-15
Authors: Christine G Parks; Frederick W Miller; Minoru Satoh; Edward K L Chan; Zhanna Andrushchenko; Linda S Birnbaum; Todd A Jusko; Grace E Kissling; Mehul D Patel; Kathryn M Rose; Clarice Weinberg; Darryl C Zeldin; Dale P Sandler Journal: Cancer Epidemiol Biomarkers Prev Date: 2014-08-01 Impact factor: 4.254
Authors: Su Yon Jung; Peter A Scott; Jeanette C Papp; Eric M Sobel; Matteo Pellegrini; Herbert Yu; Sihao Han; Zuo-Feng Zhang Journal: Cancer Prev Res (Phila) Date: 2020-09-14